Acute heart failure with low cardiac output: Can we develop a short-term inotropic agent that does not increase adverse events?

Current Heart Failure Reports

Volumn 7, Issue 3, 2010, Pages 100-109

  Campia, Umberto ^a   Nodari, Savina ^b   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; Digoxin; Inotropic drug; Istaroxime; Low cardiac output; Lusitropic drug; Myosin activator; Omecamtiv mecarbil

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIGITALIS; DIGOXIN; DOBUTAMINE; INOTROPIC AGENT; ISTAROXIME; MILRINONE; OMECAMTIV MECARBIL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE THERAPY; HEART OUTPUT; HOSPITALIZATION; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; TISSUE PERFUSION;

ACUTE DISEASE; ANIMALS; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DIGOXIN; DOBUTAMINE; ETIOCHOLANOLONE; GENE THERAPY; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-POTASSIUM-EXCHANGING ATPASE; UREA;

EID: 77955985151     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0021-9     Document Type: Review

References (50)

1. D Lloyd-Jones R Adams M Carnethon, et al. 2009 Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 480 486 10.1161/CIRCULATIONAHA.108.191259 19171871
2. MS Nieminen VP Harjola 2005 Definition and epidemiology of acute heart failure syndromes Am J Cardiol 96 5G 10G 10.1016/j.amjcard.2005.07.015 16181818
3. SF Jencks MV Williams EA Coleman 2009 Rehospitalizations among patients in the Medicare fee-for-service program N Engl J Med 360 1418 1428 10.1056/NEJMsa0803563 1:CAS:528:DC%2BD1MXjvFGju7c%3D 19339721
4. GC Fonarow JT Heywood PA Heidenreich, et al. 2007 Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002-2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 153 1021 1028 10.1016/j.ahj.2007.03.012 17540205
5. BH Greenberg WT Abraham NM Albert, et al. 2007 Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Am Heart J 154 277.e1 e8 10.1016/j.ahj.2007.05.001 Published erratum appears in Am Heart J 2007, 154:646
6. VP Harjola F Follath MS Nieminen, et al. 2010 Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure Eur J Heart Fail 12 239 248 10.1093/eurjhf/hfq002 20156940 This study reports the most recent 3- and 12-month mortality data in patients with AHF from the EuroHeart Failure Survey II
7. M Gheorghiade WT Abraham NM Albert, et al. 2006 Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2217 2226 10.1001/jama.296.18.2217 1:CAS:528:DC%2BD28XhtFKrtbzJ 17090768
8. U Elkayam G Tasissa C Binanay, et al. 2007 Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure Am Heart J 153 98 104 10.1016/j.ahj.2006.09.005 17174645
9. S Thackray J Easthaugh N Freemantle JG Cleland 2002 The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis Eur J Heart Fail 4 515 529 10.1016/S1388-9842(02)00041-7 1:CAS:528: DC%2BD38XlvF2ru7o%3D 12167393
10. M Gheorghiade F Zannad G Sopko, et al. 2005 Acute heart failure syndromes: current state and framework for future research Circulation 112 3958 3968 10.1161/CIRCULATIONAHA.105.590091 16365214
11. MM Redfield SJ Jacobsen JC Burnett Jr, et al. 2003 Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic JAMA 289 194 202 10.1001/jama.289.2.194 12517230
12. CS Rihal RA Nishimura LK Hatle, et al. 1994 Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis Circulation 90 2772 2779 1:STN:280: DyaK2M%2FoslWhsw%3D%3D 7994820
13. CM Yu JE Sanderson TH Marwick JK Oh 2007 Tissue Doppler imaging a new prognosticator for cardiovascular diseases J Am Coll Cardiol 49 1903 1914 10.1016/j.jacc.2007.01.078 17498573
14. M Wang G Yip CM Yu, et al. 2005 Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function J Am Coll Cardiol 45 272 277 10.1016/j.jacc.2004. 09.059 15653027
15. AJ Burger DP Horton T LeJemtel, et al. 2002 Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study Am Heart J 144 1102 1108 10.1067/mhj.2002.125620 1:CAS:528:DC%2BD3sXnvFWk 12486437
16. MS Cuffe RM Califf KF Adams Jr, et al. 2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 1541 1547 10.1001/jama.287.12.1541 1:CAS:528:DC%2BD38XisVegt78%3D 11911756
17. GM Felker RL Benza AB Chandler, et al. 2003 Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 997 1003 10.1016/S0735-1097(02)02968-6 1:CAS:528:DC%2BD3sXislejsLk%3D 12651048
18. R Schulz J Rose C Martin, et al. 1993 Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation Circulation 88 684 695 1:STN:280:DyaK3szjvVyqsw%3D%3D 8393390
19. F Follath JG Cleland H Just, et al. 2002 Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 196 202 10.1016/S0140-6736(02)09455-2 1:CAS:528:DC%2BD38XlsVOmt7k%3D 12133653
20. VS Moiseyev P Põder N Andrejevs, et al. 2002 Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 1422 1432 10.1053/euhj.2001.3158 1:CAS:528:DC%2BD38XotFyrtLs%3D 12208222
21. A Mebazaa MS Nieminen M Packer, et al. 2007 Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 1883 1891 10.1001/jama.297.17.1883 1:CAS:528:DC%2BD2sXkvFKrsLs%3D 17473298
22. JG Cleland N Freemantle AP Coletta AL Clark 2006 Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 105 110 10.1016/j.ejheart.2005.12.003 1:CAS:528:DC%2BD28XkvFWn 16387630
23. Withering W: An account of the foxgloves and some of its medical uses, with practical remark on dropsy, and other diseases. In Classics of Cardiology, vol 1. Edited by Willius FA, Keys TE. New York: Dover Publications; 1941:231-252.
24. EJ Eichhorn M Gheorghiade 2002 Digoxin Prog Cardiovasc Dis 44 251 266 10.1053/pcad.2002.31591 1:CAS:528:DC%2BD38XktFWntr0%3D 12007081
25. M Cattel H Gold 1938 The influence of digitalis glycosides on the force of contraction of mammalian cardiac muscle J Pharmacol Exper Ther 62 116 125
26. R Bloomfield B Rapoport JP Milnor 1948 el al.: The effects of the cardiac glycosides upon the dynamics of the circulation in congestive heart failure. I. Ouabain J Clin Invest 27 588 599 10.1172/JCI102004
27. Godraind T: Stimulation and inhibition of the Na+, K+ pump by cardiac glycosides. In Cardiac Glycosydes, Part I, Experimental Pharmacology. Edited by Greeff K. Berlin: Springer-Verlag; 1981:381-406.
28. Rocco T, Fang JC: Pharmacotherapy of congestive heart failure. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, edn 11. Chicago: McGraw-Hill; 2005:869-898.
29. Bers DM: Cardiac inotropy and Ca mismanagement. In Excitation-Contraction Coupling and Cardiac Contractile Force, edn 2. Edited by Bers DM. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2001:273-331.
30. JA Wasserstrom DE Farkas MA Norell DV Vereault 1991 Effects of different cardiac steroids on intracellular sodium, inotropy and toxicity in sheep Purkinje fibers J Pharmacol Exp Ther 258 918 925 1:CAS:528:DyaK3MXmt1eisL0%3D 1890626
31. T Sagawa K Sagawa JE Kelly, et al. 2002 Activation of cardiac ryanodine receptors by cardiac glycosides Am J Physiol Heart Circ Physiol 282 H1118 H1126 1:CAS:528:DC%2BD38Xit1Ggsrs%3D 11834511
32. M Gobbini P Barassi A Cerri, et al. 2001 17 alpha-O-(aminoalkyl)oxime derivatives of 3 beta, 14 beta-dihydroxy-5 beta-androstane and 3 beta-hydroxy-14-oxoseco-D-5 beta-androstane as inhibitors of Na(+), K(+)-ATPase at the digitalis receptor J Med Chem 44 3821 3830 10.1021/jm0109208 1:CAS:528:DC%2BD3MXntlentL4%3D 11689068
33. R Micheletti GG Mattera M Rocchetti, et al. 2002 Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane-6, 17-dione hydrochloride (PST2744) J Pharmacol Exp Ther 303 592 600 10.1124/jpet.102.038331 1:CAS:528:DC%2BD38XotlCgu7s%3D 12388640
34. M Rocchetti A Besana G Mostacciuolo, et al. 2003 Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms J Pharmacol Exp Ther 305 765 771 10.1124/jpet.102.047696 1:CAS:528:DC%2BD3sXjt12lsrg%3D 12606646
35. M Rocchetti A Besana G Mostacciuolo, et al. 2005 Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E, Z)-3-((2-aminoethoxy)imino)androstane-6, 17-dione hydrochloride] J Pharmacol Exp Ther 313 207 215 10.1124/jpet.104.077933 1:CAS:528:DC%2BD2MXjtlSnsLk%3D 15576469
36. G Hasenfuss B Pieske 2002 Calcium cycling in congestive heart failure J Mol Cell Cardiol 34 951 969 10.1006/jmcc.2002.2037 1:CAS:528: DC%2BD38XmvVanuro%3D 12234765
37. CH Davies K Davia JG Bennett, et al. 1995 Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure Circulation 92 2540 2549 1:STN:280:DyaK28%2FmvFaktg%3D%3D 7586355
38. R Micheletti F Palazzo P Barassi, et al. 2007 Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure Am J Cardiol 99 24A 32A 10.1016/j.amjcard.2006.09.003 1:CAS:528:DC%2BD2sXntlKjsQ%3D%3D 17239701
39. JK Ghali WB Smith G Torre-Amione, et al. 2007 A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function Am J Cardiol 99 47A 56A 10.1016/j.amjcard.2006.09.006 1:CAS:528:DC%2BD2sXntlKjtQ%3D%3D 17239705
40. M Gheorghiade JE Blair GS Filippatos, et al. 2008 Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure J Am Coll Cardiol 51 2276 2285 10.1016/j.jacc.2008.03.015 1:CAS:528:DC%2BD1cXmvVOgsLo%3D 18534276 This is the first study to evaluate the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime in patients hospitalized with HF. Istaroxime achieved its primary hemodynamic endpoints and confirmed its safety
41. SJ Shah JE Blair GS Filippatos, et al. 2009 Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial Am Heart J 157 1035 1041 10.1016/j.ahj.2009.03.007 1:CAS:528:DC%2BD1MXmtlOltr8%3D 19464414 This article is an analysis of the HORIZON-HF data evaluating the effects of istaroxime on LV function as measured by echocardiography. Istaroxime decreased diastolic stiffness and improved contractility and systolic and diastolic function
42. MJ Byrne JM Power A Preovolos, et al. 2008 Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals Gene Ther 15 1550 1557 10.1038/gt.2008.120 1:CAS:528:DC%2BD1cXhtlyhur%2FM 18650850
43. XH Wehrens SE Lehnart SR Reiken AR Marks 2004 Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor Circ Res 94 e61 e70 10.1161/01.RES.0000125626.33738.E2 1:CAS:528:DC%2BD2cXisFOhtLg%3D 15016728
44. N Lindegger E Niggli 2005 Paradoxical SR Ca2+ release in guinea-pig cardiac myocytes after beta-adrenergic stimulation revealed by two-photon photolysis of caged Ca2+ J Physiol 565 801 813 10.1113/jphysiol.2005.084376 1:CAS:528:DC%2BD2MXlslChs7g%3D 15774509
45. SO Marx S Reiken Y Hisamatsu, et al. 2000 PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts Cell 101 365 376 10.1016/S0092-8674(00)80847-8 1:CAS:528:DC%2BD3cXjsFekurY%3D 10830164
46. M Yano S Kobayashi M Kohno, et al. 2003 FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure Circulation 107 477 484 10.1161/01.CIR.0000044917.74408.BE 1:CAS:528:DC%2BD3sXks1eksw%3D%3D 12551874
47. XH Wehrens SE Lehnart S Reiken, et al. 2005 Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure Proc Natl Acad Sci U S A 102 9607 9612 10.1073/pnas.0500353102 1:CAS:528:DC%2BD2MXmsVaktL4%3D 15972811
48. EM DeGoma RH Vagelos MB Fowler EA Ashley 2006 Emerging therapies for the management of decompensated heart failure: from bench to bedside J Am Coll Cardiol 48 2397 2409 10.1016/j.jacc.2006.08.039 1:CAS:528:DC%2BD28Xhtlaltr3E 17174176
49. JR Teerlink 2009 A novel approach to improve cardiac performance: cardiac myosin activators Heart Fail Rev 14 289 298 10.1007/s10741-009-9135-0 1:CAS:528:DC%2BD1MXhtlKju7rI 19234787 This review details the available data on early trials of omecamtiv mecarbil
50. M Gheorghiade DJ van Veldhuisen WS Colucci 2006 Contemporary use of digoxin in the management of cardiovascular disorders Circulation 113 2556 2564 10.1161/CIRCULATIONAHA.105.560110 16735690